MYCN and neuroblastoma: Further, there were no apparent differences in outcomes among patients with MYCN amplification, although the subgroup was underrepresented in this trial population (14%) compared with a higher estimated prevalence of ≤25% in all neuroblastoma cases5,45 and ≤40% in patients with HR disease46.